Activity of clinafloxacin, compared with six other quinolones, against Acinetobacter baumannii clinical isolates

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 3, 2002, Pages 471-477

  Vila, Jordi ^a   Ribera, Anna ^a   Marco, Francesc ^a   Ruiz, Joaquim ^a   Mensa, Josep ^a   Chaves, Josep ^b   Hernandez, Gonzalo ^b   Jimenez De Anta, M Teresa ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CIPROFLOXACIN; CLINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SERINE; SPARFLOXACIN; TROVAFLOXACIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CODON; CONTROLLED STUDY; DRUG EFFECT; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

EID: 0036125317     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.3.471     Document Type: Article

References (40)

1. Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus
2. Nosocomial Acinetobacter meningitis secondary to invasive procedures: Report of 25 cases and review
3. Bacteremia with Acinetobacter species: Risk factors and prognosis in different clinical settings
4. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care units
5. An outbreak of Acinetobacter respiratory tract infection resulting from imcomplete disinfection of ventilatory equipment
6. A hospital outbreak of antibiotic resistant Acinetobacter anitratus. Epidemiology and control
7. Multiple intensive care unit outbreak of Acinetobacter calcoaceticus subspecies anitratus respiratory infection and colonization associated with contaminated, reusable ventilator circuits and resuscitation bags
8. A report of further hospital outbreak caused by a multiresistant Acinetobacter anitratus
9. Epidemiological markers of Acinetobacter baumannii clinical isolates from a spinal cord injury unit
10. Laboratory investigation of hospital outbreak caused by two different multiresistant Acinetobacter calcoaceticus subsp. anitratus strains
11. An underestimated nosocomial pathogen, Acinetobacter calcoaceticus
12. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro
13. The comparative in vitro activity of eight newer quinolones and nalidixic acid
14. Comparative in vitro activity of the new difluoroquinolone temafloxacin (A-62254) against bacterial isolates from cancer patients
15. The epidemiology of bacterial resistance to quinolones
16. Antimicrobial susceptibility of Acinetobacter species
17. Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3 and genospecies 6)
18. In vitro antimicrobial production of β-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii
19. Bactericide activity of sulbactam before bacteria belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex
20. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii
21. In vitro susceptibilities of multiresistant strains of Acinetobacter baumannii to eight quinolones
22. Molecular aspects of fluoroquinolone resistance
23. Mechanisms of antimicrobial resistance in Acinetobacter baumannii
24. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli
25. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two mutations
26. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs
27. Contribution of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals
28. The region of the parE gene, homologous to the quinolone-resistant determining region of the gyrB gene, is not linked with the acquisition of quinolone resistance in Escherichia coli clinical isolates
29. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV
30. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus
31. Active efflux of norfloxacin by Bacteroides fragilis
32. Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure
33. In vitro activity of clinafloxacin with other quinolones against Stenotrophomonas maltophilia clinical isolates in the presence and absence of reserpine
34. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., Acinetobacter junii sp. nov., and emended Acinetobacter calcoaceticus and Acinetobacter lwoffii
35. Recomendaciones del grupo MENSURA para la selección de antimicrobianos en el estudio de la sensibilidad y criterios para la interpretación del antibiograma
36. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii
37. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii
38. Molecular epidemiology of quinolone resistance in Acinetobacter sp